C4 Therapeutics, Inc.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-discovery approach that uses the body’s own protein disposal machinery to eliminate disease-causing proteins. The company’s proprietary TORPEDO platform is used to design small-molecule degraders with oral bioavailability, catalytic activity, and, in some programs, brain penetration. Its most advanced internal programs are cemsidomide for multiple myeloma and CFT8919 for EGFR L858R-mutant non-small-cell lung cancer. In addition to its wholly owned pipeline, C4 Therapeutics also generates collaboration revenue from partnerships with larger pharmaceutical companies, which helps fund ongoing research and development. The business remains pre-commercial and depends on clinical progress, regulatory success, and partner milestones to create future value.

−315,1 %

−292,1 %

+1,0 %

7.81

7.81

— C4 Therapeutics, Inc.
%
Clinical-stage oncology programs0% Wholly owned drug candidates in human testing, including cemsidomide and CFT8919.
Discovery platform and preclinical pipeline0% TORPEDO-enabled degrader design and earlier-stage programs in oncology, inflammation, neuroinflammation, and neurodegeneration.
Collaboration revenue100% Research, license, and milestone revenue from pharmaceutical partners such as Merck KGaA, Merck, Roche, Biogen, and Betta Pharma.

C4 Therapeutics does not yet sell approved medicines, so its current “customers” are collaboration partners that pay...

  • Pharmaceutical collaboration partnersprimary

    Large biopharma companies that pay for access to C4's degrader platform, research services, and milestone-based development programs.

  • Oncology patients and treating physiciansprimary

    Multiple myeloma and NSCLC patients, via oncologists and specialty centers, would be the end users of any approved internal pipeline product.

  • Third-party payorssecondary

    Commercial insurers and government programs that would determine reimbursement and access for any approved therapy.

  • Clinical investigators and research sitessecondary

    Hospitals and trial sites that conduct the company's Phase 1/2 and preclinical studies and enable program advancement.

C4 Therapeutics is headquartered in Watertown, Massachusetts and operates as a U.S.-based clinical-stage biotech...

  • •Headquartered in Watertown, Massachusetts, United States
  • •Revenue is driven by collaboration agreements with global pharma partners
  • •Clinical and discovery work depends on U.S. and foreign CROs and vendors
  • •Foreign or foreign-owned suppliers create trade and supply-chain exposure
  • •No country-level revenue split was disclosed in the provided excerpts

C4 Therapeutics is focused on advancing its internal pipeline while using collaborations to support funding and...

01
Advance lead clinical programsshort-term

Clinical data are the main driver of value for a pre-commercial biotech and determine whether the programs can reach approval or partnering.

02
Sustain collaboration revenueshort-term

Partner milestones and research payments help fund operations and reduce dependence on equity financing.

03
Expand platform and pipeline breadthmedium-term

A broader set of degrader programs increases the chance of finding commercially viable assets and reduces single-asset risk.

04
Prepare for commercializationmedium-term

If a product is approved, the company will need regulatory, manufacturing, and commercial infrastructure to capture value.

C4 Therapeutics faces the classic risks of a clinical-stage biotech: it has no approved products, no product revenue,...

critical

Clinical development failure

The company’s value depends on cemsidomide, CFT8919, and other programs demonstrating safety and efficacy in trials.

Scope
Lead oncology pipeline
Materiality
high
high

Need for additional capital

The company expects losses for several years and has no product sales to self-fund operations.

Scope
Corporate funding and dilution risk
Materiality
high
high

Third-party clinical and manufacturing dependence

CROs, trial sites, and vendors control key development activities and supply of materials.

Scope
R&D execution
Materiality
high
medium

Foreign vendor and trade exposure

Reliance on foreign or foreign-owned vendors can create sanctions, tariff, and supply disruption risk.

Scope
Clinical trial materials and discovery services
Materiality
medium
medium

Partner revenue volatility

Collaboration revenue depends on milestone achievement, program activity, and partner decisions.

Scope
Merck KGaA, Merck, Roche, Biogen, Betta
Materiality
medium
Collaboration revenue recognition
Can materially shift quarterly and annual revenue
Deferred revenue and contract termination accounting
Can distort comparability across periods
Research and development expense recognition
Major driver of operating loss volatility
Stock-based compensation
Impacts reported loss and dilution analysis
Lease liability measurement
Affects balance sheet and occupancy cost presentation

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Camp4 Therapeutics Corp

CAMP · Pharmaceutical Preparations

BICYCLE THERAPEUTICS PLC

BCYC · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

: 11/08/2026